Advocacy
SMA Patient-Focused Drug Development Meeting with FDA Set for April 18, 2017
Tuesday, April 18, 2017, has been announced as the date for the SMA Patient-Focused Drug Development Meeting with the FDA. At the Patient Focused Drug […]
Read More ›Join Us for an Upcoming Webcast about SPINRAZA TM (nusinersen)
Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the […]
Read More ›FDA Approves Spinraza for SMA
On December 23, the FDA announced that it has approved SpinrazaTM (nusinersen) to treat spinal muscular atrophy, making it the first-ever FDA-approved therapy for SMA. […]
Read More ›Cure SMA Participates in a Special FDA Listening Session
Last week, Cure SMA participated in a listening session with FDA Commissioner Robert M. Califf, MD, MACC. The FDA organized the listening session in order […]
Read More ›SMA Community Conducts Outreach Visits with Members of Congress
On November 30, members of the SMA community met with 17 different legislative offices— eight from the Senate and nine from the House of Representatives. […]
Read More ›Annual Congressional Dinner Brings SMA Community Together on the Eve of 21st Century Cure Bill Passage
On Tuesday, November 29, more than 160 people from the SMA community – including government and industry partners – gathered for the 6th Annual “Hope […]
Read More ›Help Us Shape the Future Together, and Reach our Goal of $750,000
This has been an historic year for the SMA community. On October 28, our pharmaceutical partners at Biogen and Ionis announced that their New Drug […]
Read More ›Cure SMA Launches Insurance Coverage and Payment Policy Project
Earlier this year, Cure SMA initiated an insurance coverage and payment policy project, in partnership with District Policy Group. The goal of this project is […]
Read More ›Cure SMA Joins SMA Europe and TREAT-NMD for Meeting with EMA Regulators
Cure SMA will be participating in a one-day workshop with The European Medicines Agency (EMA—the European equivalent of the FDA), SMA Europe and TREAT-NMD to […]
Read More ›Cure SMA to Host Webinar on the New Drug Application Process
On Tuesday, December 6, Cure SMA will be hosting a one-hour webinar on the New Drug Application (NDA) process. The webinar will be held at […]
Read More ›